Pharma: Other News To Note
Friday, August 31, 2012
Abbott, of Abbott Park, Ill., said the European Commission approved Humira (adalimumab) in moderately active Crohn's disease (CD) in adult patients who have not adequately responded to conventional therapy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.